Equities

InspireMD Inc

InspireMD Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.39
  • Today's Change-0.07 / -2.85%
  • Shares traded17.26k
  • 1 Year change-24.04%
  • Beta0.9340
Data delayed at least 15 minutes, as of Nov 12 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects InspireMD Inc share price to rise to 4.50 in the next year from the last price of 2.39.
High88.7%4.50
Med88.7%4.50
Low88.7%4.50

Earnings history & estimates in USD

On Nov 12, 2024, InspireMD Inc reported 3rd quarter 2024 losses of -0.16 per share. This result exceeded the -0.20 consensus loss of the one analyst covering the company and under-performed last year's 3rd quarter results by 6.67%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-3.85%
InspireMD Inc reported annual 2023 losses of -0.82 per share on Mar 05, 2024.
Average growth rate+52.58%
More ▼

Revenue history & estimates in USD

InspireMD, Inc. had 3rd quarter 2024 revenues of 1.81m. This bettered the 1.74m estimate of the one analyst covering the company. This was 46.09% above the prior year's 3rd quarter results.
Average growth rate+4.54%
InspireMD, Inc. had revenues for the full year 2023 of 6.21m. This was 20.00% above the prior year's results.
Average growth rate+20.68%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.